The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Research Report 2025
Synopsis
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The global Glucagon-like peptide 1 (GLP-1)-based Therapies market was valued at US$ 5387 million in 2023 and is anticipated to reach US$ 7350.9 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
This report aims to provide a comprehensive presentation of the global market for Glucagon-like peptide 1 (GLP-1)-based Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon-like peptide 1 (GLP-1)-based Therapies.
Report Scope
The Glucagon-like peptide 1 (GLP-1)-based Therapies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Glucagon-like peptide 1 (GLP-1)-based Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glucagon-like peptide 1 (GLP-1)-based Therapies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Glucagon-like peptide 1 (GLP-1)-based Therapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The global Glucagon-like peptide 1 (GLP-1)-based Therapies market was valued at US$ 5387 million in 2023 and is anticipated to reach US$ 7350.9 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
This report aims to provide a comprehensive presentation of the global market for Glucagon-like peptide 1 (GLP-1)-based Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon-like peptide 1 (GLP-1)-based Therapies.
Report Scope
The Glucagon-like peptide 1 (GLP-1)-based Therapies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Glucagon-like peptide 1 (GLP-1)-based Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glucagon-like peptide 1 (GLP-1)-based Therapies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Glucagon-like peptide 1 (GLP-1)-based Therapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Overview
1.1 Product Overview and Scope of Glucagon-like peptide 1 (GLP-1)-based Therapies
1.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
1.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value Comparison by Type (2024-2030)
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
1.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Estimates and Forecasts
1.4.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2019-2030
1.4.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2019-2030
1.4.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competition by Manufacturers
2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2019-2024)
2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturers (2019-2024)
2.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Product Type & Application
2.7 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation and Trends
2.7.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players Market Share by Revenue
2.7.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Glucagon-like peptide 1 (GLP-1)-based Therapies Retrospective Market Scenario by Region
3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region: 2019-2030
3.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region: 2019-2024
3.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region: 2025-2030
3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2019-2030
3.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2019-2024
3.3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2025-2030
3.4 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
3.4.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2030)
3.4.3 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
3.5.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2030)
3.5.3 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
3.6.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2030)
3.6.3 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
3.7.1 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2030)
3.7.3 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
3.8.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2030)
3.8.3 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2019-2030)
4.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2019-2024)
4.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2025-2030)
4.1.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2019-2030)
4.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2019-2030)
4.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2019-2024)
4.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2025-2030)
4.2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2019-2030)
4.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2019-2030)
5 Segment by Application
5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2019-2030)
5.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2019-2024)
5.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2025-2030)
5.1.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2019-2030)
5.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2019-2030)
5.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2019-2024)
5.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2025-2030)
5.2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2019-2030)
5.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Eli Lily
6.3.1 Eli Lily Corporation Information
6.3.2 Eli Lily Description and Business Overview
6.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.3.5 Eli Lily Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Abbott Laboratories
6.6.1 Abbott Laboratories Corporation Information
6.6.2 Abbott Laboratories Description and Business Overview
6.6.3 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.7.5 Abbott Laboratories Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
7.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Production Mode & Process
7.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Marketing
7.4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Channels
7.4.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors
7.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Customers
8 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Dynamics
8.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Trends
8.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
8.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
8.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation by Manufacturers in 2023
Table 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Glucagon-like peptide 1 (GLP-1)-based Therapies, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Product Type & Application
Table 12. Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2024) & (K Units)
Table 18. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2019-2024)
Table 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2025-2030) & (K Units)
Table 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2025-2030)
Table 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2019-2024)
Table 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2025-2030)
Table 25. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (K Units)
Table 27. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2025-2030) & (K Units)
Table 28. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (K Units)
Table 32. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2025-2030) & (K Units)
Table 33. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) by Type (2019-2024)
Table 51. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) by Type (2025-2030)
Table 52. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2019-2024)
Table 53. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2025-2030)
Table 54. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2019-2024)
Table 57. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2025-2030)
Table 58. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Type (2019-2024)
Table 59. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Type (2025-2030)
Table 60. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) by Application (2019-2024)
Table 61. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) by Application (2025-2030)
Table 62. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2019-2024)
Table 63. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2025-2030)
Table 64. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2019-2024)
Table 67. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2025-2030)
Table 68. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Application (2019-2024)
Table 69. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Application (2025-2030)
Table 70. Novo Nordisk Corporation Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product
Table 74. Novo Nordisk Recent Developments/Updates
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. Eli Lily Corporation Information
Table 81. Eli Lily Description and Business Overview
Table 82. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product
Table 84. Eli Lily Recent Developments/Updates
Table 85. GSK Corporation Information
Table 86. GSK Description and Business Overview
Table 87. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product
Table 89. GSK Recent Developments/Updates
Table 90. Sanofi Corporation Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product
Table 94. Sanofi Recent Developments/Updates
Table 95. Bristol-Myers Squibb Corporation Information
Table 96. Bristol-Myers Squibb Description and Business Overview
Table 97. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product
Table 99. Bristol-Myers Squibb Recent Developments/Updates
Table 100. Abbott Laboratories Corporation Information
Table 101. Abbott Laboratories Description and Business Overview
Table 102. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product
Table 104. Abbott Laboratories Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors List
Table 108. Glucagon-like peptide 1 (GLP-1)-based Therapies Customers List
Table 109. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Trends
Table 110. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
Table 111. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
Table 112. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 2. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type in 2023 & 2030
Figure 4. Exenatied Product Picture
Figure 5. Liraglutide Product Picture
Figure 6. Lixisenatide Product Picture
Figure 7. Albiglutide Product Picture
Figure 8. Dulaglutide Product Picture
Figure 9. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application in 2023 & 2030
Figure 11. Hospital
Figure 12. Pharmacy
Figure 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (2019-2030) & (US$ Million)
Figure 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (2019-2030) & (K Units)
Figure 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (US$/Unit) & (2019-2030)
Figure 17. Glucagon-like peptide 1 (GLP-1)-based Therapies Report Years Considered
Figure 18. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Manufacturers in 2023
Figure 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players: Market Share by Revenue in 2023
Figure 21. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2019-2030)
Figure 24. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2019-2030)
Figure 25. United States Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2019-2030)
Figure 28. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2019-2030)
Figure 29. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2019-2030)
Figure 36. China Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. China Taiwan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2019-2030)
Figure 46. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2019-2030)
Figure 56. Global Revenue Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2019-2030)
Figure 57. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Application (2019-2030)
Figure 59. Global Revenue Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Application (2019-2030)
Figure 60. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Application (2019-2030)
Figure 61. Glucagon-like peptide 1 (GLP-1)-based Therapies Value Chain
Figure 62. Glucagon-like peptide 1 (GLP-1)-based Therapies Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
